Development of a homotrimeric PSMA radioligand based on the NOTI chelating platform

Abstract Background The NOTI chelating scaffold can readily be derivatized for bioconjugation without impacting its metal complexation/radiolabeling properties making it an attractive building block for the development of multimeric/-valent radiopharmaceuticals. The objective of the study was to fur...

Full description

Bibliographic Details
Published in:	EJNMMI Radiopharmacy and Chemistry
Main Authors:	Sebastian Martin, Moritz-Valentin Schreck, Tobias Stemler, Stephan Maus, Florian Rosar, Caroline Burgard, Andrea Schaefer-Schuler, Samer Ezziddin, Mark D. Bartholomä
Format:	Article
Language:	English
Published:	SpringerOpen 2024-12-01
Subjects:	NOTI Bifunctional chelator Gallium-68 PSMA Trimer Multimerization
Online Access:	https://doi.org/10.1186/s41181-024-00314-7

Similar Items

Tolerability of PSMA radioligand therapy in metastatic prostate cancer patients with baseline mild to moderate leukopenia
by: Moritz B. Bastian, et al.
Published: (2025-07-01)

Change of glucometabolic activity per PSMA expression predicts survival in mCRPC patients non-responding to PSMA radioligand therapy: introducing a novel dual imaging biomarker
by: Caroline Burgard, et al.
Published: (2024-01-01)

Dual FDG/PSMA PET imaging to predict lesion-based progression of mCRPC during PSMA-RLT
by: Florian Rosar, et al.
Published: (2024-05-01)

Efficacy and Safety of [<sup>225</sup>Ac]Ac-PSMA-617 Augmented [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis
by: Florian Rosar, et al.
Published: (2021-05-01)

Response Assessment and Prediction of Progression-Free Survival by <sup>68</sup>Ga-PSMA-11 PET/CT Based on Tumor-to-Liver Ratio (TLR) in Patients with mCRPC Undergoing <sup>177</sup>Lu-PSMA-617 Radioligand Therapy
by: Fadi Khreish, et al.
Published: (2021-07-01)

Bifunctional gallium cation chelators
by: A. G. Polivanova, et al.
Published: (2022-06-01)

Modern Developments in Bifunctional Chelator Design for Gallium Radiopharmaceuticals
by: Patrick R. W. J. Davey, et al.
Published: (2022-12-01)

PSMA-Positive Follicular Thyroid Carcinoma Incidentally Detected by [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT: Correlation with Immunohistology Confirms Neovascular PSMA-Expression
by: Florian Rosar, et al.
Published: (2022-05-01)

[89Zr]Zr-PSMA-617 PET/CT characterization of indeterminate [68Ga]Ga-PSMA-11 PET/CT findings in patients with biochemical recurrence of prostate cancer: lesion-based analysis
by: Florian Rosar, et al.
Published: (2024-02-01)

Active Lumbar Spondylodiscitis on [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT Mimicking Bone Metastasis
by: Florian Rosar, et al.
Published: (2023-12-01)

Histologically Confirmed Testicular Metastasis Revealed by [<sup>89</sup>Zr]Zr-PSMA-617 PET/CT in a Patient with Biochemical Recurrence of Prostate Cancer and Negative Conventional PSMA PET/CT Imaging
by: Florian Rosar, et al.
Published: (2023-04-01)

[<sup>89</sup>Zr]Zr-PSMA-617 PET/CT in a Patient with Biochemical Recurrence of Prostate Cancer and Prior Indetermined Findings on [<sup>18</sup>F]PSMA-1007 Imaging
by: Moritz B. Bastian, et al.
Published: (2024-10-01)

Pharmacological Optimization of PSMA-Based Radioligand Therapy
by: Suzanne van der Gaag, et al.
Published: (2022-11-01)

Association between Escherichia coli with NotI-restriction resistance and urinary tract infections
by: Masayuki Hashimoto, et al.
Published: (2022-08-01)

Outstanding increase in tumor-to-background ratio over time allows tumor localization by [89Zr]Zr-PSMA-617 PET/CT in early biochemical recurrence of prostate cancer
by: Caroline Burgard, et al.
Published: (2024-10-01)

Automated radiolabelling of [68Ga]Ga-PSMA-11 (gallium (68Ga)-gozetotide) using the Locametz® kit and two generators
by: Elke A. van Brandwijk, et al.
Published: (2024-04-01)

Radiochemical and Biological Evaluation of 3p-<i>C</i>-NETA-ePSMA-16, a Promising PSMA-Targeting Agent for Radiotheranostics
by: Erika Murce, et al.
Published: (2023-06-01)

A bivalent spike-targeting nanobody with anti-sarbecovirus activity
by: Iris C. Swart, et al.
Published: (2025-03-01)

177Lu-PSMA radioligand therapy for isolated bilateral adrenal metastases from prostate cancer
by: Elisabetta Perrone, et al.
Published: (2024-07-01)

Design, Synthesis, and Evaluation of Linker-Optimised PSMA-Targeting Radioligands
by: Fanny Lundmark, et al.
Published: (2022-05-01)

Competition (‘Steal’ Phenomenon) between [<sup>68</sup>Ga]Ga-PSMA-11 Uptake in Prostate Tumor Tissue Versus Healthy Tissue
by: Esmée C. A. van der Sar, et al.
Published: (2021-05-01)

Application of targeted diagnosis of PSMA in the modality shift of prostate cancer diagnosis: a review
by: Li Yan, et al.
Published: (2023-09-01)

Synthesis and Preclinical Evaluation of Two Novel <sup>68</sup>Ga-Labeled Bispecific PSMA/FAP-Targeted Tracers with 2-Nal-Containing PSMA-Targeted Pharmacophore and Pyridine-Based FAP-Targeted Pharmacophore
by: Arsyangela Verena, et al.
Published: (2024-02-01)

PSMA Targeted Molecular Imaging and Radioligand Therapy for Prostate Cancer: Optimal Patient and Treatment Issues
by: Seiji Hoshi, et al.
Published: (2023-08-01)

Necessity of Pelvic Lymph Node Irradiation in Patients with Recurrent Prostate Cancer after Radical Prostatectomy in the PSMA PET/CT Era: A Narrative Review
by: Naeim Nabian, et al.
Published: (2022-12-01)

Differences in Distribution and Detection Rate of the [<sup>68</sup>Ga]Ga-PSMA Ligands PSMA-617, -I&T and -11—Inter-Individual Comparison in Patients with Biochemical Relapse of Prostate Cancer
by: Falk Gühne, et al.
Published: (2021-12-01)

Revolutionizing Prostate Cancer Detection: The Role of Approved PSMA-PET Imaging Agents
by: Ute Hennrich, et al.
Published: (2025-06-01)

Albumin-Binding PSMA Radioligands: Impact of Minimal Structural Changes on the Tissue Distribution Profile
by: Luisa M. Deberle, et al.
Published: (2020-05-01)

Refined Chelator Spacer Moieties Ameliorate the Pharmacokinetics of PSMA-617
by: José Carlos dos Santos, et al.
Published: (2022-08-01)

Case Report: Long-term complete response to PSMA-targeted radioligand therapy and abiraterone in a metastatic prostate cancer patient
by: David Parker, et al.
Published: (2023-04-01)

Pretherapeutic PSMA PET-Derived Semiquantitative Parameters as Predictors of PSA Response in Patients with mCRPC Receiving [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy
by: Dheeratama Siripongsatian, et al.
Published: (2024-10-01)

A pilot study of 68 Ga-PSMA-617 PET/CT imaging and 177Lu-EB-PSMA-617 radioligand therapy in patients with adenoid cystic carcinoma
by: Guochang Wang, et al.
Published: (2022-08-01)

Hybrid Chelator-Based PSMA Radiopharmaceuticals: Translational Approach
by: Hanane Lahnif, et al.
Published: (2021-10-01)

Molecular basis for multimerization in the activation of the epidermal growth factor receptor
by: Yongjian Huang, et al.
Published: (2016-03-01)

A Review on the Current State and Future Perspectives of [<sup>99m</sup>Tc]Tc-Housed PSMA-i in Prostate Cancer
by: Sara Brunello, et al.
Published: (2022-04-01)

The therapeutic use of 177 Lu-PSMA-617 radioligand therapy in prostate cancer treatment: a review of literature and ongoing trials
by: Alexander Konopnicki, et al.
Published: (2024-12-01)

All that glitters is not gold: high uptake on PSMA PET in non-prostate cancers does not mean that treatment with [177Lu]Lu-PSMA-radioligand will be successful
by: Trond Velde Bogsrud, et al.
Published: (2024-10-01)

Assessment of salivary gland function after 177Lu-PSMA radioligand therapy: Current concepts in imaging and management
by: Sonia Mahajan, et al.
Published: (2022-07-01)

Standardization of the [<sup>68</sup>Ga]Ga-PSMA-11 Radiolabeling Protocol in an Automatic Synthesis Module: Assessments for PET Imaging of Prostate Cancer
by: Leonardo L. Fuscaldi, et al.
Published: (2021-04-01)

Synthesis of Bispidine-Based Prostate-Specific Membrane Antigen-Targeted Conjugate and Initial Investigations
by: Aleksei E. Machulkin, et al.
Published: (2025-02-01)